VEGFA and age-related macular degeneration: Beyond monogenic disease, AAV is also being used to vectorize anti-vascular endothelial growth factor (VEGF) reagents to the retina via SRI to serve as a one-time treatment for the neovascular form of AMD (wet AMD).